Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Tumor Immunotherapy01:27

Tumor Immunotherapy

660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer Vaccines01:30

Cancer Vaccines

509
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
509
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Skin Cancer01:30

Skin Cancer

4.5K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.5K
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

High-sensitivity X-ray imaging based on cost-effective and large-size CZT epitaxial crystal.

Materials horizons·2026
Same author

Development and Internal Validation of a Machine Learning-Based Classification Model for Identifying Cognitive Frailty in Older Inpatients with Type 2 Diabetes Mellitus.

Clinical interventions in aging·2026
Same author

Two Fatty Acids From Host Plant Leaves Are Attractive to Soritia leptatina Adults.

Journal of chemical ecology·2026
Same author

Predicting adolescent suicidal tendency in Chinese secondary school students: a machine learning approach with XGBoost and SHAP interpretation.

BMC public health·2026
Same author

Autophagy and multimodal programmed cell death and their crosstalk in ulcerative colitis.

Tissue & cell·2026
Same author

Interpretable machine learning-driven optimization of physicochemical properties in hydrogel scaffolds to promote macrophage polarization.

Biomaterials translational·2026

Video Experimental Relacionado

Updated: Sep 10, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.5K

Inmunoterapia en el tratamiento del melanoma

Yan Xing1, Helena T Wu2,3, Swapnil Rajurkar3

  • 1City of Hope Comprehensive Cancer Center, Duarte, CA, USA. yxing@coh.org.

Cancer treatment and research
|August 23, 2025
PubMed
Resumen
Este resumen es generado por máquina.

Los tratamientos sistémicos para el melanoma cutáneo, incluida la inmunoterapia y las terapias dirigidas, mejoran la supervivencia en entornos neoadyuvantes, adyuvantes y en estadio IV. La selección del tratamiento se guía por la etapa de la enfermedad y el estado de la mutación BRAF.

Palabras clave:
AdyuvanteLa mutación BRAFEn el caso de los fármacosLa inmunoterapiaIpilimumab y sus derivadosEl melanomaNuevo adyuvanteEl tratamiento con NivolumabEstadio IV del melanomaTerapia dirigida

Más Videos Relacionados

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.1K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.8K

Videos de Experimentos Relacionados

Last Updated: Sep 10, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.5K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.1K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.8K

Área de la Ciencia:

  • En el campo de la oncología
  • Dermatología
  • La inmunoterapia

Sus antecedentes:

  • El tratamiento del melanoma cutáneo ha evolucionado significativamente con las terapias sistémicas.
  • Comprender las estrategias óptimas para las diferentes etapas de la enfermedad es crucial para los resultados de los pacientes.

Objetivo del estudio:

  • Revisar las estrategias actuales de tratamiento sistémico para el melanoma cutáneo.
  • Para discutir los enfoques de tratamiento neoadyuvante, adyuvante y de la Etapa IV.
  • Para resaltar la eficacia, la toxicidad y las terapias emergentes.

Principales métodos:

  • Revisión de las modalidades de tratamiento sistémico para el melanoma cutáneo.
  • Análisis de las terapias en entornos neoadyuvantes, adyuvantes y metastásicos.
  • Incluir datos sobre inhibidores de los puntos de control inmunológicos y terapias dirigidas.

Principales resultados:

  • La terapia neoadyuvante con nivolumab más ipilimumab muestra altas tasas de respuesta.
  • La inmunoterapia adyuvante y la terapia dirigida mejoran la supervivencia libre de recaída en el melanoma de alto riesgo.
  • El tratamiento de la etapa IV utiliza inmunoterapia y inhibidores de la vía MAPK basados en el estado de BRAF.

Conclusiones:

  • Las terapias sistémicas mejoran significativamente la supervivencia y los intervalos libres de tratamiento en el melanoma cutáneo.
  • La selección del tratamiento se personaliza en función de la etapa de la enfermedad y los marcadores moleculares.
  • Las terapias emergentes como los linfocitos que se infiltran en el tumor ofrecen vías de tratamiento futuras.